

European Journal of Pharmaceutics and Biopharmaceutics

Official Journal of
International Association of Pharmaceutical Technology (APV) and
European Association of Pharma Biotechnology (EAPB)

The *European Journal of Pharmaceutics and Biopharmaceutics* provides a medium for publication of novel and innovative research from areas of pharmaceutical technology, drug delivery systems, controlled release systems, drug targeting, physical pharmacy, biopharmaceutics, pharmacodynamics and pharmacokinetics, drug development, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, GMP, regulatory aspects, pharmaceutical packaging, and phytochemistry.

A special section on Pharmaceutical Biotechnology was started in 2003 and provides a forum for the publication of papers on scientific, developmental, regulatory and manufacturing issues concerning the development of biopharmaceuticals, uniquely combining expert contributions and opinions of authors from the fields of pharmaceutics and biotechnology. This scope encompasses modern biopharmaceuticals (e.g., proteins and nucleic acids), biosimilars/biogenics as well as 'traditional' products such as antibiotics.

EJPB Editorial Team:

Editor-in-Chief:

R. Gurny, School of Pharmaceutical Sciences, University of Geneva

USA Editor:

J.W. McGinity, College of Pharmacy, Drug Dynamics Institute, University of Texas at Austin, Austin, TX

Pacific Rim Editor:

Y. Kawashima, Gifu Pharmaceutical University, Department of Chemical Engineering, Gifu, Japan

European Editors:

Achim Göpferich, Institute of Pharmacy, Pharmaceutical Technology, University of Regensburg, Germany

G. Lee, Institute for Pharmaceutical Technology, University of Erlangen-Nürnberg, Erlangen, Germany

C.M. Lehr, Univ. of Saarland, Dept of Biopharmaceutics & Pharmaceutical Technology, Saarbrücken, Germany

Section Editor, Pharmaceutical Biotechnology:

G. Borchard, School of Pharmaceutical Sciences, University of Geneva

Associate Editor:

M. Möller, School of Pharmaceutical Sciences, University of Geneva

EJPB articles are indexed and abstracted in:

- BIOSIS /Biological Abstracts
- CAB Abstracts
- Chemical Abstracts Service
- Current Contents/Life Sciences
- EMBASE/Excerpta Medica
- International Pharmaceutical Abstracts
- PUBMED/Medline/Index Medicus
- PASCAL M
- Science Citation Index Expanded

Latest Impact Factor = 1.877

EJPB regularly publishes Theme Issues on such hot topics as:

- Biomaterials
- Drug delivery
- Microencapsulation
- Pharmaceutical biotechnology
- Coating and solid dosage forms
- Drug targeting
- Peptides and proteins
- Powder technology

The *special benefits* you'll receive when you contribute to *EJPB* are:

- Rapid publication time – corrected proofs are typically online within 6-8 weeks of acceptance
- Maximum exposure via ScienceDirect (with its 10 million users worldwide)
- Increased visibility for your paper via ContentsDirect, the free e-mail service which delivers Elsevier book and journal table of contents directly to the registrant's desk top
- No page charges
- 50 free reprints of your article
- Free use of colour in ScienceDirect (black and white in print)

Quick and Easy Submission Procedure

Visit the journal website at <http://authors.elsevier.com/journal/ejpb> and follow the step by step instructions on how to submit your manuscript via the online submission system.

Selection of Pharmaceutical Biotechnology Papers Published in 2003-2005

Pharmaceutical biotechnology products approved within the European Union
G. Walsh, 55/1, Jan 2003 (Review)

Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing
M. Irngartinger, V. Camuglia, M. Damm, J. Goede, H. W. Frijlink
58/1, July 2004

Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus
A. Lamprecht, H. Yamamoto, H. Takeuchi, Y. Kawashima
58/1, July 2004

Second-generation biopharmaceuticals
G. Walsh
58/2, September 2004 (Review article)

Localized delivery of growth factors for bone repair
V. Luginbuehl, L. Meinel, H.P. Merkle, B. Gander
58/2, September 2004 (Review article)

Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing *Lactococcus lactis*
N. Huyghebaert, A. Vermeire, S. Neiryneck, L. Steidler, E. Remaut, J.P. Remon
59/1, January 2005

Formulation development of inhalation powders for FK999 using the E-haler® to improve the inhalation performance at a high dose, and its absorption in healthy volunteers
T. Nakate, H. Yoshida, A. Ohike, T. Tolunaga, R. Ibuki, Y. Kawashima
59/1, January 2005

The therapeutic antibodies market to 2008
A.K. Pavlou, M.J. Belsey
59/3, April 2005

Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective
M. Närhi, K. Nordström
59/3, April 2005

Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development
O. Nieminen, P. Kurki, K. Nordström
60/3, August 2005

Pharmacokinetic comparison of two recombinant human granulocyte colony-stimulating factors after subcutaneous administration in rabbits
J. Duconge, L. Rodriguez-Vera, C. Valenzuela, D. Alvarez, O. Ramirez, K.R. de la Luz-Hernandez, E.Y. Rabeza-Legon, A. Casaco, E. Fernandez-Sanchez
61/3, October 2005

For full-text articles, please visit: www.sciencedirect.com/science/journal/09396411

Register for free e-mail alerts of the tables-of contents at: <http://contentsdirect.elsevier.com>